Creative Medical Technology Holdings Inc

NASDAQ CELZ

Data sourced from iex and EODHD
Download Data

Creative Medical Technology Holdings Inc Debt to Equity Ratio for the year ending December 31, 2023

Creative Medical Technology Holdings Inc Debt to Equity Ratio is NA for the year ending December 31, 2023. The debt to equity ratio measures the proportion of a company's financing that comes from debt relative to shareholders' equity. It is calculated by dividing total debt by shareholders' equity. This ratio provides insights into the company's capital structure and the degree of financial leverage. A higher ratio suggests a higher level of debt financing in relation to equity.
NASDAQ: CELZ

Creative Medical Technology Holdings Inc

CEO Mr. Timothy Warbington
IPO Date Nov. 6, 2015
Location United States
Headquarters 211 East Osborn Road, Phoenix, AZ, United States, 85012
Employees 4
Sector Healthcare
Industry Biotechnology
Description

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

StockViz Staff

September 19, 2024

Any question? Send us an email